Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 4/20 | 0.35 |
| ▸ | MMP14 | P50281 | 4/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5181022 | 1.00 | ALDH1A1 (0.39) | ALDH1A1MMP13MMP14TNFPARP1 | |
| SCHEMBL5181883 | 0.74 | AR (0.42) | ALDH1A1CYP2D6SMN1; SMN2NPSR1 | |
| SCHEMBL5182333 | 0.73 | ADRB2 (0.38) | CYP2D6 | |
| SCHEMBL5183217 | 0.73 | ADRB2 (0.38) | CYP2D6 | |
| SCHEMBL5183206 | 0.73 | ADRB2 (0.38) | CYP2D6 | |
| SCHEMBL5183453 | 0.72 | GSK3A (0.43) | HRH3 | |
| SCHEMBL5182582 | 0.72 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL5180747 | 0.69 | PTPN2 (0.46) | ALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL4802684 | 0.69 | CA1 (0.48) | — | |
| SCHEMBL6818777 | 0.69 | DDB1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1366025-B1 | AGONISTS OF BETA-ADRENORECEPTORS | GLAXO GROUP LTD (GB) | 2007-06-27 | — | — | EP | disclosed |
| US-7144908-B2 | Agonists of beta-adrenoceptors | GLAXO GROUP LIMITED (GB) | 2006-12-05 | — | — | US | disclosed |
| US-20040242890-A1 | Agonists of beta-adrenoceptors | GLAXO GROUP LIMITED (GB) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242890-A1 | Agonists of beta-adrenoceptors | ADRB1, ADRB2, ADRA1A | ALDH1A1 360/4885MMP13 4648/4885MMP14 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.